Neurocrine Biosciences, Inc. (NBIX) is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company's two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women's health that is partnered with AbbVie Inc. (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. The Company focuses on developing NBI-640756 against Essential tremor. Its research and development focuses on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric diseases. Its Corticotropin-Releasing Factor (CRF) is a hypothalamic hormone released directly into the hypophyseal portal vasculature.
Analyst Upgrade/Downgrade Update Brokerage firm: Needham Change: Coverage Initiated Previous Rating: N/A Current Rating: Buy Previous Price Target: N/A Current Price Target: $62
@T0rm3nted you did it again! Biotech stock Neurocrine surges more than 22% after FDA approves first drug for movement disorder Biotech gets FDA approval for first drug to treat movement disorder tardive dyskinesia, or TD. Neurocrine shares were up 7 percent on the year before the announcement. Disorder causes uncontrollable, abnormal and repetitive movements in certain upper body muscles.
